Eli Lilly in United States — Neurology: the full competitive set, and the 1 AXLRx report covering them with market-access, payer and competitive detail, every figure verified to a live source.
Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
We use analytics cookies to see how visitors use AXLRx. They're only set if you accept — decline and none are placed. See our Privacy Policy.